27 results
8-K
EX-99.1
HEPA
Hepion Pharmaceuticals Inc
27 May 22
Regulation FD Disclosure
8:44am
rencofilstat doses and matched placebo arm (84 subjects/arm) 125 sites selected to target a 12-14 month recruitment Final country selection: US, Germany … to allow for increased review of tissue for ballooning, etc. Other Considerations: With long recruitment and trial conduct for biopsy readout, interim
8-K
EX-99.2
3dmp9wtg
13 Sep 21
Regulation FD Disclosure
8:28am
8-K
EX-99.1
q1fgfaz2bew3o 7bw
6 May 21
Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH
10:14am
8-K
n4mi9jy
6 May 21
Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH
10:14am
8-K
EX-99.1
sdo9pndwm9f6p0rg
23 Mar 21
Other Events
8:21am
FWP
ft1fvuf740etjo2bmut
18 Nov 20
Free writing prospectus
5:29pm
FWP
ir33wmxjvt
12 Nov 20
Free writing prospectus
5:27pm
8-K
EX-99.1
5gh6u cz5zs15r7
1 Oct 20
Regulation FD Disclosure
4:27pm
10-KT
ivriy
26 Mar 18
Annual report (with FYE transition)
12:00am
424B5
p22 rd7nxg3n6
7 Oct 15
Prospectus supplement for primary offering
12:00am